Search

Displaying results 6731 - 6740 of 10000 in total
  1. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. … This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.

  2. Drug

    Radotermin

    go.drugbank.com/drugs/DB19127
    Investigational

    Radotermin is under investigation in clinical trial NCT01182337 (A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal Rhgdf-5 for the

  3. Target

    Folate receptor alpha

    go.drugbank.com/bio_entities/BE0003405
    TargetTransporterHumans

    Required for normal embryonic development and normal cell proliferation (By similarity) … Has high affinity for folate and folic acid analogs at neutral pH (PubMed:23851396, PubMed:23934049, PubMed:2527252, PubMed:8033114, PubMed:8567728).

    Synonyms: FOLR
  4. Drug

    QXL138AM

    go.drugbank.com/drugs/DB18552
    Investigational

    QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.

    Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a
  5. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752] … AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  6. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797] … Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.

    Synonyms: AUTOLOGOUS HUMAN DERMAL FIBROBLAST CELLS DERIVED FROM SKIN BIOPSIES, AND TRANSDUCED WITH A NON-REPLICATING, SELF-INACTIVATING LENTIVIRUS VECTOR THAT ENCODES HUMAN COLLAGEN TYPE VII ALPHA 1 (COL7A1) UNDER, TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
  7. Drug

    Tulisokibart

    go.drugbank.com/drugs/DB18719
    Investigational

    It is being investigated for ulcerative colitis. … PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.

  8. Drug

    Icalcaprant

    go.drugbank.com/drugs/DB21651
    Investigational

    Icalcaprant is under investigation in clinical trial NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder … Icalcaprant is a small molecule drug. The usage of the INN stem '-caprant' in the name indicates that Icalcaprant is a kappa-opioid receptor (KOR) antagonist.

  9. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  10. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug. … AI-128 is the first human demonstration of sustained release drug administration in the lung.